Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …

Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …

Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …

Banked acute-phase and convalescent-phase serum samples from a previous study of
respiratory illness in university students were examined for significant (≥2-fold) increases in …

Chlamydia pneumoniae (TWAR) is a recently recognized third species of the genus Chlamydia
that causes acute respiratory disease. It is distinct from the other two chlamydial species …

Reductions in pain ratings when administered a placebo with expected analgesic
properties have been described and hypothesized to be mediated by the pain-suppressive …